CSL Limited (ASX:CSL)
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
CSL Limited (ASX:CSL) share price
CSL Limited (ASX:CSL) share price news
ASX 200 morning report – NVX, CSL & TPG shares in focus
The S&P/ASX 200 (ASX: XJO) bucked the trend to gain 0.2% on Friday as Novonix (ASX:NVX) and CSL (AS:CSL) shares were in the news.
CSL (ASX:CSL) share price in focus on potential multi-billion Swiss acquisition
The CSL Limited (ASX:CSL) share price is in focus on reports that it could be about to make a multi-billion acquisition of Vifor Pharma.
Dividend growth investing aristocrat: Washington H. Soul Pattinson (ASX:SOL)
Washington H. Soul Pattinson (ASX: SOL) is almost a dividend aristocrat and has increased its dividend for 21 years – the longest consecutive streak of the ASX.
Why I prefer these ASX shares to VAS ETF
There are quite a few ASX shares that I prefer compared to Vanguard Australian Shares Index ETF (ASX:VAS).
Dividend growth investing and share buybacks: Amcor (ASX:AMC)
Share buybacks are often-overlooked by management, though can turbocharge your dividend growth investing if properly executed.
ASX 200 morning report – BHP, SYD & SDR shares in focus
The S&P/ASX 200 (ASX: XJO) experienced a rare loss on Monday as SiteMinder (ASX:SDR) and Sydney Airport (ASX:SYD) shares made headlines.
3 keys to unlocking long term value creation
The three keys to long term value creation are no hidden secret: profit growth, changes in valuation multiples, and cash flow contributions.
ASX 200 set to fall – A2M, WOW & VUL shares in focus
The S&P/ASX 200 (ASX:XJO) managed to eke out another small gain on Wednesday as Woolies (ASX:WOW) and a2 Mik (ASX:A2M) shares made headlines.
The prisoner’s dilemma: value or value trap?
It’s a Sunday evening, a glass of red in hand, and I was watching Oaktree’s Howard Marks opine on markets,